Acomplia (Rimonabant) - Investigational Agent for the Management of Obesity
Key Data:
Drug (brand/generic)
Acomplia / rimonabant
Company/licensee
Sanofi-Aventis
Therapy class
Cannabinoid receptor antagonist
Product description
Selective inhibitor of the CB1 endocannabinoid receptor
Current indication
Treatment of obesity in combination with dietary control
Market sector
Nutrition
Development status
Approved in Europe, pre-registration in the US
